Meeting
2018 ASCO Annual Meeting
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
Authors
Michael Carleton
Bristol-Myers Squibb, Princeton, NJ
Michael Carleton , Ming Zhou , Olivier De Henau , Penny Phillips , Tian Chen , Ye Feng , Shu-Pang Huang , Alice Walsh , Timothy P. Reilly , Ignacio Melero Bermejo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3025)
DOI
10.1200/JCO.2018.36.15_suppl.3025
Abstract #
3025
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.
First Author: Ignacio Melero Bermejo
Poster
2022 ASCO Annual Meeting
Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.
First Author: Kim Leitzel
Poster
2013 ASCO Annual Meeting
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
First Author: Joseph Grosso
Poster
2023 ASCO Annual Meeting
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
First Author: Yuval Shaked